CEO Michel Vanbrabant will illustrate the latest results for iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device MINIject at the Glaucoma Innovation Showcase today. iSTAR Medical was selected as one of eight companies to showcase innovative glaucoma treatments to prospect investors at today’s meeting organised by the Ophthalmology Innovation Summit (OIS).
iSTAR Medical recently announced consistently positive safety and efficacy outcomes in over 130 patients implanted with MINIject, and presented subsets of these data at the European Society of Cataract and Refractive Surgery (ESCRS) meeting.
“MIGS are the most promising and fastest-growing therapy for glaucoma,” explained Vanbrabant, “we are truly excited about the latest, promising data in a larger patient population that tout MINIject as potentially best-in-class.”
OIS facilitates meaningful exchange of information to accelerate the development of novel therapies that address unmet clinical needs. It was founded by ophthalmologist/venture capitalist Emmett Cunningham of Blackstone Life Sciences and venture capitalist Bill Link of Versant Ventures/Flying L Partners.
Registration is free for the OIS glaucoma innovation showcase meeting: click here.